Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions. The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions. Read More
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at GE HealthCare (NASDAQ:GEHC) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
Over the past six months, Hologic’s stock price fell to $65.75. Shareholders have lost 17.6% of their capital, which is disappointing considering the S&P 500 has climbed by 6.4%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET).
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the other hand, next quarter’s revenue guidance of $1 billion was less impressive, coming in 3.2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.
